Mrs Pamela Baker, MAED CCC/SLP | |
5890 Left Fork Maces Creek Rd, Viper, KY 41774-8458 | |
(606) 439-2520 | |
Not Available |
Full Name | Mrs Pamela Baker |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 5890 Left Fork Maces Creek Rd, Viper, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1891106159 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 1086 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Pamela Baker, MAED CCC/SLP 5890 Left Fork Maces Creek Rd, Viper, KY 41774-8458 Ph: (606) 439-2520 | Mrs Pamela Baker, MAED CCC/SLP 5890 Left Fork Maces Creek Rd, Viper, KY 41774-8458 Ph: (606) 439-2520 |
News Archive
Longitudinal monitoring of 30 tests for marker candidates in early Parkinson's disease has found that just 10 show significant changes commensurate with disease progression.
Men with first-episode psychosis have more severe symptoms than women and are less likely to achieve recovery, say Danish researchers.
Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.
Sharing of electronic health information across every major emergency department in the Memphis, Tenn., area resulted in reduced hospital admissions, reduced radiology tests and an annual cost savings of nearly $2 million, according to a Vanderbilt study released today by the Journal of the American Medical Informatics Association.
Scientists at the University of Wisconsin-Madison have developed a pair of rapid-fire tests for botulinum toxin, a feat that could underpin new technologies to thwart bioterrorism and spur the development of agents to blunt the toxic action of the world's most poisonous substance.
› Verified 7 days ago